These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
494 related articles for article (PubMed ID: 37788737)
1. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions. Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737 [TBL] [Abstract][Full Text] [Related]
2. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
3. Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions. Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdasait S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Sawyer WG bioRxiv; 2023 Feb; ():. PubMed ID: 36865164 [TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
5. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
6. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900 [TBL] [Abstract][Full Text] [Related]
7. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290 [TBL] [Abstract][Full Text] [Related]
8. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. Zhang PF; Wang C; Zhang L; Li Q Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284 [TBL] [Abstract][Full Text] [Related]
9. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
10. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Hong M; Talluri S; Chen YY Curr Opin Biotechnol; 2023 Dec; 84():103020. PubMed ID: 37976958 [TBL] [Abstract][Full Text] [Related]
11. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Giordano Attianese GMP; Ash S; Irving M Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063 [TBL] [Abstract][Full Text] [Related]
12. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Das S; Valton J; Duchateau P; Poirot L Front Immunol; 2023; 14():1172681. PubMed ID: 37251405 [TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. Johnson A; Townsend M; O'Neill K Cells; 2022 Nov; 11(22):. PubMed ID: 36429054 [TBL] [Abstract][Full Text] [Related]
14. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208 [TBL] [Abstract][Full Text] [Related]
16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
17. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model. Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529 [TBL] [Abstract][Full Text] [Related]
18. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Zhou S; Sun H; Choi SI; Yin J Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells applied to solid tumors. Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y Front Immunol; 2022; 13():984864. PubMed ID: 36389701 [TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]